Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Rethinking new therapies for Crohn’s disease at U.Va.

12.11.2004


In a Perspective article in the Nov. 11 issue of the New England Journal of Medicine, Dr. Fabio Cominelli, chief of the division of gastroenterology and hepatology at the University of Virginia Health System reports that a dysregulated response by the innate immune system- the body’s initial, non-specific response to infection- may have more to do with the development of Crohn’s than acquired immunity, currently thought by many to be the most likely suspect.



Patients, physicians and medical researchers need to reconsider traditional hypotheses about the biological processes that underlie Crohn’s disease, according to Cominelli, a leading Crohn’s expert. More than half a million people in the U.S. suffer from Crohn’s,a chronic disease involving inflammation of the intestines.

Cominelli indicates that more cytokines- proteins that coordinate the immune response in inflammation- may be involved in Crohn’s than scientists had previously thought. He believes that a growing body of evidence shows that both type 1 and type 2 helper T-cells are likely involved in the early stages of Crohn’s disease. The classic paradigm held that cytokines secreted by type 1 T-cells, such as TNF (tumor necrosis factor), interleukin-12 and interferon-g were primarily responsible for Crohn’s, while type 2 cytokines were linked to ulcerative colitis, another type of inflammatory bowel disease.


Although the underlying cause of Crohn’s remains unclear, Cominelli describes an intriguing hypothesis in which a defective innate immune system may be an important player. This could mean that blocking specific type 1 cytokines in the initial phases of Crohn’s “may not be beneficial and could actually aggravate the existing disease process,” he writes.

Cominelli emphasizes that there are questions about infliximab, the first biological therapeutic approved to treat Crohn’s, which blocks the production of the type 1 cytokine TNF. He points out that infliximab therapy does not relieve Crohn’s symptoms or induce remission in some patients. Plus, type 1 cytokines are important in combating infections, and blocking them can reactivate latent tuberculosis in some patients.

Cominelli also warns that anti-cytokine therapy in general may increase the long-term risk of cancer, and blocking some cytokines may reactivate asthma. “An effective treatment strategy for such patients might involve the blockade of multiple cytokines in order to intervene in several pathways,” he concludes.

Bob Beard | EurekAlert!
Further information:
http://www.virginia.edu

More articles from Health and Medicine:

nachricht Organ-on-a-chip mimics heart's biomechanical properties
23.02.2017 | Vanderbilt University

nachricht Researchers identify cause of hereditary skeletal muscle disorder
22.02.2017 | Klinikum der Universität München

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Breakthrough with a chain of gold atoms

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

In the field of nanoscience, an international team of physicists with participants from Konstanz has achieved a breakthrough in understanding heat transport

Im Focus: DNA repair: a new letter in the cell alphabet

Results reveal how discoveries may be hidden in scientific “blind spots”

Cells need to repair damaged DNA in our genes to prevent the development of cancer and other diseases. Our cells therefore activate and send “repair-proteins”...

Im Focus: Dresdner scientists print tomorrow’s world

The Fraunhofer IWS Dresden and Technische Universität Dresden inaugurated their jointly operated Center for Additive Manufacturing Dresden (AMCD) with a festive ceremony on February 7, 2017. Scientists from various disciplines perform research on materials, additive manufacturing processes and innovative technologies, which build up components in a layer by layer process. This technology opens up new horizons for component design and combinations of functions. For example during fabrication, electrical conductors and sensors are already able to be additively manufactured into components. They provide information about stress conditions of a product during operation.

The 3D-printing technology, or additive manufacturing as it is often called, has long made the step out of scientific research laboratories into industrial...

Im Focus: Mimicking nature's cellular architectures via 3-D printing

Research offers new level of control over the structure of 3-D printed materials

Nature does amazing things with limited design materials. Grass, for example, can support its own weight, resist strong wind loads, and recover after being...

Im Focus: Three Magnetic States for Each Hole

Nanometer-scale magnetic perforated grids could create new possibilities for computing. Together with international colleagues, scientists from the Helmholtz Zentrum Dresden-Rossendorf (HZDR) have shown how a cobalt grid can be reliably programmed at room temperature. In addition they discovered that for every hole ("antidot") three magnetic states can be configured. The results have been published in the journal "Scientific Reports".

Physicist Dr. Rantej Bali from the HZDR, together with scientists from Singapore and Australia, designed a special grid structure in a thin layer of cobalt in...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Booth and panel discussion – The Lindau Nobel Laureate Meetings at the AAAS 2017 Annual Meeting

13.02.2017 | Event News

Complex Loading versus Hidden Reserves

10.02.2017 | Event News

International Conference on Crystal Growth in Freiburg

09.02.2017 | Event News

 
Latest News

Stingless bees have their nests protected by soldiers

24.02.2017 | Life Sciences

New risk factors for anxiety disorders

24.02.2017 | Life Sciences

MWC 2017: 5G Capital Berlin

24.02.2017 | Trade Fair News

VideoLinks
B2B-VideoLinks
More VideoLinks >>>